Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Merel Jebbink

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Pharmaceutical Research|August 17, 2022
Exposure-Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life SettingRené J Boosman, Merel Jebbink, Wouter B Veldhuis, et al.
JTO Clinical and Research Reports|December 1, 2021
Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLCLiesbeth M Hondelink, Merel Jebbink, Jan H von der Thüsen, et al.
Neuro-Oncology|August 7, 2024
Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases studyJ W Tijmen van der Wel, Mirjam C Boelens, Merel Jebbink, et al.
Ebiomedicine|January 31, 2021
Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical responseFloris Dammeijer, Cornedine J De Gooijer, Mandy van Gulijk, et al.
JTO Clinical and Research Reports|March 29, 2024
Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced <i>EGFR</i>-Mutated NSCLCJudith L Gulikers, G D Marijn Veerman, Merel Jebbink, et al.
JTO Clinical and Research Reports|August 12, 2025
Longitudinal Circulating Tumor DNA-Guided Resistance Analysis During Second-Line Osimertinib TreatmentJ W Tijmen van der Wel, Merel Jebbink, Vincent van der Noort, et al.
Eclinicalmedicine|May 1, 2023
Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancerG D Marijn Veerman, Rene J Boosman, Merel Jebbink, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Pharmaceutical Research|August 17, 2022
Exposure-Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life SettingRené J Boosman, Merel Jebbink, Wouter B Veldhuis, et al.
JTO Clinical and Research Reports|December 1, 2021
Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLCLiesbeth M Hondelink, Merel Jebbink, Jan H von der Thüsen, et al.
Neuro-Oncology|August 7, 2024
Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases studyJ W Tijmen van der Wel, Mirjam C Boelens, Merel Jebbink, et al.
Ebiomedicine|January 31, 2021
Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical responseFloris Dammeijer, Cornedine J De Gooijer, Mandy van Gulijk, et al.
JTO Clinical and Research Reports|March 29, 2024
Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced <i>EGFR</i>-Mutated NSCLCJudith L Gulikers, G D Marijn Veerman, Merel Jebbink, et al.
JTO Clinical and Research Reports|August 12, 2025
Longitudinal Circulating Tumor DNA-Guided Resistance Analysis During Second-Line Osimertinib TreatmentJ W Tijmen van der Wel, Merel Jebbink, Vincent van der Noort, et al.
Eclinicalmedicine|May 1, 2023
Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancerG D Marijn Veerman, Rene J Boosman, Merel Jebbink, et al.
Pageof 1